Evidence map›Paper›PMID 38287908›Full record

ArticleCancer science2024

Regulator of G protein signaling 1 is a potential target in gastric cancer and impacts tumor-associated macrophages.

Mengting Wu, Xuefei Xu, Chuqi Yang, Qingwen An, Jingcheng Zhang, Zhengqi Zhao, Yewen Feng, Weiyu Liang, Yufei Fu, Guangji Zhang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Mengting WuSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.ORCID https://orcid.org/0000-0002-7111-8028
Xuefei XuSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Chuqi YangSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Qingwen AnSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Jingcheng ZhangSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Zhengqi ZhaoSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Yewen FengSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Weiyu LiangSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Yufei FuSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.ORCID https://orcid.org/0000-0001-9849-4739
Guangji ZhangSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Tao JiangSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Zhejiang Chinese Medical University · CN

Funding

National Natural Science Foundation of China 82030119Youth fund-National Natural Science Foundation 82204950Zhejiang Provincial Natural Science Foundation 2019C03072Zhejiang Provincial Natural Science Foundation LY22H290005
6 · The paper itself

Abstract

Regulator of G protein signaling 1 (RGS1) is closely associated with the tumor immune microenvironment and is highly expressed in various tumors and immune cells. The specific effects of RGS1 in the dynamic progression from chronic gastritis to gastric cancer have not been reported, and the role of tumor-associated macrophages (TAMs) is also unclear. In the present study, RGS1 was identified as an upregulated gene in different pathological stages ranging from chronic gastritis to gastric cancer by using Gene Expression Omnibus (GEO) screening together with pancancer analysis of The Cancer Genome Atlas and clinical prognostic analysis. The results indicated that RGS1 is highly expressed in gastric cancer and has potential prognostic value. We confirmed through in vivo experiments that RGS1 inhibited the proliferation of gastric cancer cells and promoted apoptosis, which was further corroborated by in vitro experiments. Additionally, RGS1 influenced cell migration and invasion. In our subsequent investigation of RGS1, we discovered its role in the immune response. Through analyses of single-cell and GEO database data, we confirmed its involvement in immune cell regulation, specifically TAM activation. Subsequently, we conducted in vivo and in vitro experiments to confirm the involvement of RGS1 in polarizing M1 macrophages while indirectly regulating M2 macrophages through tumor cells. In conclusion, RGS1 could be a potential target for the transformation of chronic gastritis into gastric cancer and has a measurable impact on TAMs, which warrants further in-depth research.

Indexed as

GastritisStomach NeoplasmsGTP-Binding ProteinsHumansSignal TransductionTumor-Associated MacrophagesTumor MicroenvironmentGTP-Binding Proteinsgastric cancerinflammation–cancer transitionRGS1tumor‐associated macrophagetumor microenvironment

Identifiers

PMID38287908
PMCPMC11006993
OpenAlexW4391354346

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.